Tuberculosis, Multidrug-Resistant Clinical Trial
Official title:
An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
Verified date | October 2019 |
Source | Janssen Pharmaceutical K.K. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to explore safety and efficacy of TMC207 administered as part of a multi-drug regimen for 24 to 48-week treatment in Japanese participants with pulmonary multi-drug resistant tuberculosis (MDR-TB), and to evaluate pharmacokinetics (PK) of TMC207 and its primary metabolite M2.
Status | Completed |
Enrollment | 6 |
Est. completion date | November 8, 2018 |
Est. primary completion date | November 8, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Must have confirmed pulmonary multi-drug resistant tuberculosis (MDR-TB) infection, which is defined as infection by a strain of M. tuberculosis resistant to both rifampicin and isoniazid (RFP and INH) by previous screening from a TB treatment - Must have confirmed positive results for acid-fast bacilli (AFB) on direct smear examination of expectorated sputum specimen (more than [>] 1+ smear-positive) during the Screening Phase or sputum culture positive for M. tuberculosis within the preceding 3 months - A women must not be of childbearing potential: postmenopausal or permanently sterilized or otherwise be incapable of pregnancy, or if childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods and a man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control - Must be willing and able to adhere to the prohibitions and restrictions specified in this protocol - Must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study Exclusion Criteria: - Has any concomitant severe illness or rapidly deteriorating health condition, including immune deficiency that would make implementation of the protocol or interpretation of the study results difficult or otherwise make the subject a poor candidate for a clinical study - Has complicated or severe extra-pulmonary manifestations of TB, including central nervous system infection - Participants with significant cardiac arrhythmia requiring medication - Participants with the abnormal electrocardiogram (ECG) parameters as defined in protocol - Has human immuno deficiency virus (HIV) antibody positive during the Screening Phase |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Janssen Pharmaceutical K.K. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Sputum Culture Conversion | Sputum culture conversion is defined as 2 consecutive negative cultures from sputa collected at least 25 days apart. | Week 24 | |
Secondary | Number of Participants With Multidrug resistant (MDRTB) Outcome | Outcome is defined as, Cured: Participants who completed the study and has been consistently culture-negative (at least 5 consecutive negative cultures) for at least 48 weeks. If only 1 positive culture is reported in that time, participant may still be considered cured, provided that this positive culture is followed by a minimum of 3 consecutive negative cultures. Treatment failure: Participants who completed the study and was not cured. Death: Participants who died during study. Participants reported as dead during survival follow-up before or within Week 126 window were included in this category. Participants reported as dead during after Week 126 window are not included in this category as event occurred after planned duration (126 weeks) of study. Transfer out/Default: Participants who discontinued from study for any reason. Treatment completed: Participants who completed the study but did not meet definition for cure or treatment failure due to lack of bacteriologic results. | Week 102 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05871489 -
Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Active, not recruiting |
NCT04179500 -
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
|
Phase 2 | |
Completed |
NCT03086486 -
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
|
Phase 3 | |
Completed |
NCT01201941 -
Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru
|
N/A | |
Completed |
NCT03303963 -
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
|
||
Completed |
NCT02413931 -
Nosocomial Transmission of MDR-TB in Bucharest, Romania
|
||
Recruiting |
NCT05306223 -
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
|
Phase 4 | |
Completed |
NCT02573350 -
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
|
Phase 2 | |
Completed |
NCT02597621 -
Biomarkers for Therapy Response in Drug-resistant Tuberculosis
|
||
Recruiting |
NCT05555303 -
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
|
Phase 2 | |
Recruiting |
NCT03828201 -
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
|
Phase 2 | |
Recruiting |
NCT01212003 -
Training Protocol on the Natural History of Tuberculosis
|
||
Terminated |
NCT03237182 -
The Individualized M(X) Drug-resistant TB Treatment Strategy Study
|
Phase 4 | |
Completed |
NCT03338621 -
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05007795 -
Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis
|
N/A | |
Completed |
NCT03728725 -
Xpert MTB/XDR Clinical Evaluation Trial
|
||
Completed |
NCT02589782 -
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
|
Phase 2/Phase 3 | |
Recruiting |
NCT02619994 -
Treatment Shortening of MDR-TB Using Existing and New Drugs
|
Phase 2 | |
Completed |
NCT01918397 -
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
|
Phase 2 |